Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Immunogen
Mirvetuximab soravtansine-gynx is an antibody-drug conjugate in which a chimeric IgG1 antibody binds folate receptor alpha, and a microtubule inhibitor, DM4, is attached by a cleavable linker. After internalization, DM4 is released inside the cell, disrupting the microtubule network, causing cell cycle arrest and apoptotic death. It is studied in ovarian, fallopian tube and primary peritoneal cancers.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 14, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05483933 | Phase 1 | Platinum-resistant Ovarian Cancer | Completed | STTK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Epithelial Ovarian CancerFallopian Tube CancerOvarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal Carcinoma